Certainly, the effectiveness of CFTR gene-addition per se has been validated clinically by the UK CF Gene Therapy Consortium (Alton et al., 2015), and that group has undertaken extensive preparation for clinical trials of lung CFTR gene-addition using a SIV LV vector. This evidence concerns the gene CFTR and cystic fibrosis.